Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials

Circulation. 2021 Oct 12;144(15):1265-1267. doi: 10.1161/CIRCULATIONAHA.121.054669. Epub 2021 Aug 16.
No abstract available

Keywords: chronic kidney disease; diabetes mellitus; heart failure.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzhydryl Compounds / adverse effects*
  • Benzhydryl Compounds / pharmacology
  • Benzhydryl Compounds / therapeutic use
  • Glucosides / adverse effects*
  • Glucosides / pharmacology
  • Glucosides / therapeutic use
  • Heart Failure / complications*
  • Heart Failure / drug therapy
  • Humans
  • Kidney / drug effects*

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin

Associated data

  • ClinicalTrials.gov/NCT03448406
  • ClinicalTrials.gov/NCT03448419